Literature DB >> 29296842

Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Justine M Kahn1, Nmazuo W Ozuah2, Kieron Dunleavy3, Tara O Henderson4, Kara Kelly5, Ann LaCasce6.   

Abstract

Lymphomas are responsible for approximately 20% to 25% of annual cancer diagnoses in the adolescent and young adult (AYA) population. In 2006, the National Cancer Institute and the Lance Armstrong Foundation developed a joint Adolescent and Young Adult Oncology Progress Review Group (AYAO-PRG) to formally address the unique cancer burden of patients age 15 to 39 years. As part of their recommendations, the AYAO-PRG identified 5 imperatives for improving outcomes of AYAs with cancer. Broadly, the recommended areas of focus included research, awareness and education, investigational infrastructure, care delivery, and advocacy. In response to the challenges highlighted by the AYAO-PRG, the Lymphoma Research Foundation held the first AYA Lymphoma Research Foundation Symposium on 2 October 2015. At this symposium, clinicians and basic scientists from both pediatric and adult disciplines gave presentations describing the state of the science and proposed a collaborative research agenda built on the imperatives proposed by the AYAO-PRG. The following review presents an in-depth discussion of lymphoma management across pediatric and adult oncologic disciplines, focusing on Hodgkin lymphoma, mature B-cell lymphomas, and anaplastic large cell lymphoma.

Entities:  

Year:  2017        PMID: 29296842      PMCID: PMC5728148          DOI: 10.1182/bloodadvances.2017008748

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  107 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.

Authors:  Karen S Fernández; Cindy L Schwartz; Lu Chen; Louis S Constine; Allen Chauvenet; Pedro A de Alarcón
Journal:  Pediatr Blood Cancer       Date:  2017-06-14       Impact factor: 3.167

3.  Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Stephen M Ansell
Journal:  Am J Hematol       Date:  2014-07       Impact factor: 10.047

4.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.

Authors:  Cindy L Schwartz; Lu Chen; Kathleen McCarten; Suzanne Wolden; Louis S Constine; Robert E Hutchison; Pedro A de Alarcon; Frank G Keller; Kara M Kelly; Tanya A Trippet; Stephan D Voss; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2016-10-27       Impact factor: 3.167

6.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

7.  Hodgkin's disease in the very young.

Authors:  S F Cleary; M P Link; S S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

8.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors:  Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

9.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  8 in total

Review 1.  Current considerations in AYA Hodgkin lymphoma.

Authors:  Jennifer L Crombie; Ann S LaCasce
Journal:  Br J Haematol       Date:  2018-11-20       Impact factor: 6.998

2.  ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data.

Authors:  Aaron J Storey; Kevin S Naceanceno; Renny S Lan; Charity L Washam; Lisa M Orr; Samuel G Mackintosh; Alan J Tackett; Rick D Edmondson; Zhengyu Wang; Hong-Yu Li; Brendan Frett; Samantha Kendrick; Stephanie D Byrum
Journal:  Mol Omics       Date:  2020-04-29

3.  Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population-based study.

Authors:  Justine M Kahn; Frances B Maguire; Qian Li; Renata Abrahão; Jamie E Flerlage; Elysia Alvarez; Theresa H M Keegan
Journal:  Cancer       Date:  2021-09-08       Impact factor: 6.860

Review 4.  How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.

Authors:  Satish Gopal; Thomas G Gross
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

Review 5.  Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.

Authors:  Justine M Kahn; Kara M Kelly
Journal:  Pediatr Blood Cancer       Date:  2018-03-30       Impact factor: 3.167

Review 6.  Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.

Authors:  Kieron Dunleavy; Thomas G Gross
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

7.  ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.

Authors:  M S A Amin; O Brunckhorst; C Scott; D Wrench; M Gleeson; M Kazmi; K Ahmed
Journal:  Clin Transl Oncol       Date:  2020-09-17       Impact factor: 3.405

8.  Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study.

Authors:  Renata Abrahão; Qian W Li; Marcio H Malogolowkin; Elysia M Alvarez; Raul C Ribeiro; Ted Wun; Theresa H M Keegan
Journal:  Br J Haematol       Date:  2020-02-20       Impact factor: 8.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.